Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s DiseaseJack D. Scott, Andrew W. Stamford, J. Wayne Meredith et al.|Journal of Medicinal Chemistry|2016Cited by 165
Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitorJared N. Cumming, Andrew W. Stamford, Elizabeth M. Smith et al.|Bioorganic & Medicinal Chemistry Letters|2012Cited by 153
Discovery of Cyclic Acylguanidines as Highly Potent and Selective β-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part I—Inhibitor Design and ValidationZhaoning Zhu, John C. Hunter, Z. J. Sun et al.|Journal of Medicinal Chemistry|2009Cited by 121
Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical Library Design to Identify Novel μM Leads for the Development of nM BACE-1 (β-Site APP Cleaving Enzyme 1) InhibitorsYu‐Sen Wang, Daniel F. Wyss, Corey Strickland et al.|Journal of Medicinal Chemistry|2009Cited by 102
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ ReductionAndrew W. Stamford, William J. Greenlee, Jack D. Scott et al.|ACS Medicinal Chemistry Letters|2012Cited by 99